bone-fracture healing 3, 8, [10] [11] [12] [13] . These alloys or BMGs, composed of magnesium, calcium, zinc and strontium, have good corrosion resistance-and thus presumably minor hydrogen production-after implantation into the bone 3, 14 . However, whether magnesium actively contributes to the observed osteogenic effects of these alloys or BMGs remains unclear because other composited elements (such as strontium) are also reported to promote bone formation 15, 16 . Therefore, in the present study, we used ultrapure magnesium and investigated its possible effects on bone formation, as well as the underlying molecular mechanism.
In long bones, the periosteum, a connective tissue membrane covering the outer surface of bone, has been shown to be important to the integrity, modeling and remodeling of bone, particularly during fracture repair 17 , because a large number of mesenchymal stem cells essential for osteogenesis are from the cambium layer of the periosteum. These cells are known as periosteum-derived stem cells (PDSCs) 18 . In addition, the periosteum contains sensory nerves that release neuropeptides known to be involved in osteogenesis 19, 20 . Among them, CGRP is suggested to be the most important osteoanabolic peptide 21 . Of note, our previous studies have shown that the implantation of magnesium-based alloys or BMGs into the distal femur in rodents gives rise to increased cortical-bone thickness, with new bone formed at the peripheral cortex next to the periosteum 3, 10, 12 . We therefore speculated that magnesium might be released from the intramedullary implant into the periosteum, and that PDSCs and sensory nerves in the periosteum might have a role in magnesiuminduced bone formation.
To provide magnesium implants with sustained mechanical strength for the fixation and healing of long-bone fractures, we also developed an innovative intramedullary nail (IMN) containing magnesium (Mg-IMN) and investigated its effect on fracture healing in rats with ovariectomy-induced osteoporosis.
RESULTS

Role of the periosteum in magnesium-induced bone formation
We first used a nonfractured femur model to confirm the osteogenic effect of magnesium. We surgically implanted either a 99.99%-pure magnesium rod or, as a control, a stainless steel rod into the medullary cavity of the intact femur in rats. At week 2 after surgery, µX-ray fluorescence ( Supplementary Fig. 1a-d ) and scanning electron microscopy ( Supplementary Fig. 1e-h ) revealed a remarkably higher magnesium concentration in the cortical bone and bone-periosteum junction of the magnesium-implanted femora, as compared to that of the controls, which suggests the diffusion of magnesium from the implant across the bone toward the periosteum. Meanwhile, H&E staining and calcein labeling showed a substantially larger amount of new bone formation, mainly at the peripheral cortex, in magnesium-implanted femora, as compared to the controls (Fig. 1a) . Micro-computed tomography (CT) measurements confirmed significantly higher total bone tissue volume (TV), high-density bone volume (BV) and ρ-moment of inertia (ρMOI) in magnesium-implanted femora, as compared to that in controls (Fig. 1b,c) .
To evaluate the role of the periosteum in magnesium-induced new-bone formation, we surgically removed the periosteum when magnesium rods were implanted. As a result, new bone was no longer formed at regions where the periosteum had been removed successfully, and was instead found only at peripheral cortex that contained residual periosteum, as shown by both radiographs and micro-CT (Fig. 1b,c and Supplementary Fig. 2a ).
CGRP is involved in magnesium-induced bone formation
To test the possible role of sensory nerves in the periosteum in the osteogenic effect of magnesium, we destroyed the sensory nerves by injecting high-dose capsaicin into the dorsal spine in rats, as previously reported 22 . Consequently, the degree of magnesium-induced new-bone formation was significantly lower than that in the group without capsaicin treatment (Fig. 1d,e) . Moreover, similarly to the effect of implanted magnesium rods, the injection of MgCl 2 (10 mM in a volume of 100 µl, daily for 3 d) directly at one side of the L3-L5 lumbar spine also induced new bone formation at the peripheral cortex of the ipsilateral femur (Supplementary Fig. 2b) . In magnesium-implanted femora at week 2 after surgery, immunofluorescence staining showed abundant CGRP in peripheral cortical bone, whereas in controls, only scattered CGRP labeling was found (Fig. 1f) . ELISA analysis showed that the concentration of CGRP in bone tissues was higher after magnesium implantation, which peaked at day 4 with a value eight-fold higher than the controls, and was lower at day 7 and 14, as compared to day 4, but the values were still two-fold higher than the controls (Fig. 1f) . In addition, at week 2 after surgery, substantially higher expression of CGRP was also found in L4 DRGs in rats with magnesium implantation, as compared to the controls (Fig. 1g) .
We also measured the concentrations of other sensory neuropeptides, including substance P, neurokinins and galanin, in implanted femora, given that beneficial effects on bone healing have also been reported for these 23, 24 . ELISA analysis showed that the concentration of substance P was higher by approximately one-fold at day 4, whereas neurokinin K and galanin were not notably different after magnesium implantation, as compared to the control group ( Supplementary  Fig. 2c ). These results suggest that CGRP might be the predominant neuropeptide contributing to magnesium-induced bone formation. To test this idea, we injected BIBN4096BS (BIBN, 750 µg/ml in a volume of 100 µl, every other day), a CGRP-receptor antagonist, into rat femora in conjunction with magnesium implantation, which resulted in substantially lower TV and BV values in magnesium-implanted femora than in the non-BIBN-treated group ( Supplementary Fig. 2d-f) .
To further confirm the involvement of CGRP and its receptor in magnesium-induced osteogenesis, we injected complementary DNA (cDNA)-conjugated and short interfering RNA (shRNA)-conjugated adenovirus to overexpress or knockdown calcitonin receptor-like receptor (Calcrl) or receptor activity-modifying protein 1 (Ramp1, the direct binding site for CGRP) in rat femur in vivo ( Supplementary  Fig. 3 ). An in vivo imaging system revealed that fluorescent adenoviruses conjugated with Calcrl (AdV-Calcrl) or shRNA targeting Calcrl (AdV-shCalcrl) were located at the injected femur with some diffusion to the contralateral femur, yet were undetectable in major metabolic organs (Supplementary Fig. 3a ). PCR and western blot assays confirmed successful overexpression or knockdown of Calcrl or Ramp1 in the femora (Supplementary Fig. 3b,c) . As shown by radiographs (Fig. 2a) and calcein/xylenol double labeling (Fig. 2b) , Calcrl overexpression by AdV-Calcrl further enhanced magnesium-induced new-bone formation, whereas its knockdown by AdV-shCalcrl attenuated this process. According to micro-CT analysis, significantly greater TV and BV, with no difference in BV/TV or bone mineral density (BMD), were observed in magnesium-implanted femora in conjunction with Calcrl overexpression by AdV-Calcrl, as compared to the magnesium-implanted femora treated with scrambled adenoviruses as a negative control (AdV-NC) (Fig. 2c) . Conversely, significantly lower TV was found in the AdVshCalcrl-treated and magnesium-implanted femora than in the 1 1 6 2 VOLUME 22 | NUMBER 10 | OCTOBER 2016 nAture medicine magnesium-implanted femora co-treated with AdV-NC (Fig. 2c) . Furthermore, we observed substantially greater amounts of calcein-labeled new bone and significantly higher TV and BV in magnesium-implanted femora with Ramp1-overexpression by AdV-Ramp1, whereas we observed less calcein-labeling with significantly lower TV and BV in those with Ramp1-knockdown by AdV-shRamp1, as compared to the magnesium-implanted femora treated with AdV-NC. (Fig. 2d,e) . CGRP is encapsulated by synaptic vesicles and released from the axon terminals of DRG neurons 25, 26 . Thus, we evaluated the effect of magnesium on synaptic-vesicle aggregation in DRG neurons isolated from rats (Fig. 3a) . Immunofluorescence labeling revealed CGRP expression in isolated DRG neurons (Fig. 3b) . The synaptic vesicles in the DRG neurons were labeled with a fluorescent dye, FM1-43, and monitored with a live-cell confocal system. In the absence of magnesium ions (Mg 2+ ) in the bath, FM1-43-labeled vesicles were seen mainly in neuron bodies. Upon the addition of MgCl 2 (1 mM) into the bath, FM1-43 intensity at neuronal terminals was increased within 5 min. Subsequently, another 1 mM MgCl 2 was added to reach an accumulative concentration of 2 mM, which induced further increase in FM1-43 intensity at neuronal terminals ( Fig. 3c and Supplementary Video 1), and thus suggests that Mg 2+ induces the movement and aggregation of these vesicles toward neuronal terminals. Because N-methyl-d-glucamin (NMDG) is a cellmembrane nonpermeable cation, NMDG-Cl was added as a control, which induced no obvious effect on FM1-43 intensity at neuronal terminals, excluding the involvement of Cl − in this process (Supplementary Fig. 4a ). In addition, Zn 2+ and Mn 2+ , two divalent cations similar to Mg 2+ , inhibited, rather than promoted, FM1-43-labeled vesicle aggregation (Supplementary Fig. 4b,c) . Moreover, the effect of Mg 2+ on vesicle aggregation was abolished in cells pretreated with cytochalasin B (Fig. 3d) , which inhibits actin polymerization 27 . In addition, the intracellular ATP concentration was elevated after treating the isolated DRG neurons with Mg 2+ (Fig. 3e) . These results therefore suggest that Mg 2+ might promote synaptic-vesicle aggregation by enhancing ATP-facilitated actin polymerization.
To Figure 1 Periosteum-dependent new-bone formation induced by magnesium in rat femur. (a) Representative H&E staining (top) and calcein-green labeling (bottom) for new bone in the mid-shaft of rat femora intramedullary implanted with a magnesium (Mg 2+ ) or stainless steel (as control (Ctrl)) rod for 2 weeks (n = 6 images per group). P, periosteum; BM, bone marrow; OB, old bone; NB, new bone. Scale bars, 200 µm. (b,c) Representative micro-CT images (b, n ≥ 7 images per group) and corresponding measurements (c) of total bone TV, high-density BV and ρMOI in rat femora implanted with Mg 2+ or Ctrl rods, or denuded of the periosteum with magnesium implantation (Mg 2+ minus periosteum). ***P < 0.001 by one-way ANOVA with Tukey's post hoc test. Parenthetic numbers indicate n value for each group. Scale bars, 1 mm. Stainless-steel implants were removed from the bone before micro-CT to avoid scanning artifact. (d,e) Representative radiographs (d, n ≥ 6 images per group) and micro-CT measurements of TV, BV and BMD (e) in rat femora 2 weeks after Mg 2+ or Ctrl implantation with or without capsaicin treatment (see Online Methods). *P < 0.05, ***P < 0.001 by one-way ANOVA with Tukey's post hoc test. n is shown for each group in parentheses. Scale bars, 5 mm. mg HA/cm 3 , unit of hydroxyapatite density.
(f) Representative immunofluorescence labeling (top, n = 1 image from each of three rats per group used) and ELISA analysis (bottom) for CGRP in rat femora 2 weeks after implantation. Arrowheads indicate CGRP-positive area. **P < 0.01, ***P < 0.001 by two-way ANOVA with Bonferroni post hoc test, n = 3 biological replicates. Scale bars, 50 µm. (g) Representative images of immunofluorescence staining (n = 1 image from each of three rats per group used) for CGRP in DRGs in L4 lumbar from rats at 2 weeks after implantation. 
CGRP promotes the osteogenic differentiation of PDSCs
In magnesium-implanted femora, we detected numerous cells at the region between the periosteum and newly formed bone (Fig. 4a) , which are presumably PDSCs. We isolated the cells from the periosteum of rat femora, and they were positively labeled with stem cell markers (Supplementary Fig. 5 ), which suggests that they are PDSCs. Consistently with results in vivo, alkaline phosphatase (ALP) and alizarin red (AR) staining showed greater osteogenic differentiation capacity of PDSCs isolated from magnesium-implanted rat femora, as compared to those from stainless-steel-implanted (as control, Ctrl) or nonimplanted (as blank control, Blk) femora (Fig. 4b) .
To verify a role for CGRP in the mediation of magnesium-induced osteogenesis, we examined the effects of CGRP on isolated PDSCs. First, no increase in the proliferation of PDSCs by CGRP (up to 10 −8 M) was observed (Fig. 4c) . We next induced osteogenic differentiation of PDSCs in the presence of CGRP. Real-time PCR results showed that the treatment of PDSCs with CGRP (10 −12 -10 −8 M) for 2 weeks significantly promoted transcription of the osteogenic markers Alp, Bglap and Opn in a concentration-dependent manner (Fig. 4d) . As shown by ALP and AR staining, the CGRP-induced osteogenic differentiation of PDSCs was promoted by AdV-based overexpression of Calcrl or Ramp1 and diminished by their knockdown ( Fig. 4e and Supplementary Fig. 3d ). , calcein/xylenol assessment of bone remodeling (b, n = 1 image from each of four rats per group used) and micro-CT measurements of BV, TV and BMD (c) in rat femora 2 weeks after Mg 2+ or Ctrl implantation, with pretreatment with adenoviruses conjugated with Calcrl cDNA (AdV-Calcrl) or shRNA targeting Calcrl (AdV-shCalcrl) to overexpress or knockdown Calcrl, respectively. Adenovirus with scrambled sequence was used as the negative control (AdV-NC). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., P > 0.05 by one-way ANOVA with Newman-Keuls post hoc test. n = 4 animals per group. Scale bars, 5 mm (a) and 1 mm (b). (d,e) Representative calcein-green labeling for new bone (d, n = 6 images per group) and micro-CT measurements of BV, TV and BMD (e) in rat femora 2 weeks after Mg 2+ or Ctrl implantation with the pretreatment of adenoviruses conjugated with Ramp1 cDNA (AdV-Ramp1), shRNA targeting Ramp1 (AdV-shRamp1) or AdV-NC, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, n.s., P > 0.05 by one-way ANOVA with Newman-Keuls post hoc test. n = 6 animals per group. Scale bars, 500 µm (d). Data throughout are means ± s.e.m. Activation of the CGRP receptor initiates the cyclic adenosine monophosphate (cAMP)-signaling pathway, which can lead to phosphorylation of the transcription factor CREB1 (ref. 33) , which subsequently activates Sp7 transcription factor (SP7, also known as Osterix) and runt-related transcription factor 2 (RUNX2), two other transcription factors that are known to be crucial for osteogenesis 34, 35 . We therefore examined these transcription factors in CGRP-treated PDSCs. Western blot results showed that treatment with CGRP (10 −10 M, 72 h) resulted in greater levels of phosphorylated (p) CREB1 and SP7 in PDSCs as compared to those without CGRP treatment, which was blunted by AdV-shCalcrl-induced Calcrl knockdown (Fig. 4f) . No remarkable change in RUNX2 expression was found (Fig. 4f) .
We also examined the effect of conditioned medium from DRG neuron cultures on the osteogenic differentiation of PDSCs. DRG neurons were cultured in the absence or presence of MgCl 2 (2 mM) for 3 d before the conditioned medium was collected. As shown by ALP and AR staining, treating the PDSCs with Mg 2+ -conditioned, neuronal-culture medium facilitated the cells' osteogenic differentiation, as compared to cells treated with the control medium, and this facilitation was inhibited in cells with Calcrl knocked down by AdV-shCalcrl (Fig. 4g) .
Mg-IMN promotes fracture healing
In spite of the observed osteogenic effects, pure magnesium rods failed to fix long-bone fractures in mice 3 weeks after implantation ( Supplementary Fig. 6a ), probably owing to degradation of the rod and thus deterioration of its mechanical strength over time. To translate the osteogenic effect of magnesium for orthopedic application, we developed a 'bioactive' Mg-IMN by inserting a magnesium rod into a hollow IMN made of stainless steel with holes drilled in the middle of the nail as vents for magnesium release ( Supplementary Fig. 6b,c) . Finite elemental analysis (FEA) of the designed Mg-IMN suggested that its mechanical strength was comparable to that of nondrilled nails ( Supplementary Fig. 6d ).
We then tested the ability of the Mg-IMN system to heal fractured femurs in rats with ovariectomy-induced osteoporosis, as compared to an IMN implant without a magnesium insert. Given the suggested involvement of the periosteum in the beneficial effects of magnesium on fracture healing, we used a closed femora fracture model (see Online Methods) in which the periosteum remained intact during bone injury. We first confirmed diffusion of magnesium from the Mg-IMN system into the bone and the periosteum ( Supplementary  Fig. 6e ), as was seen similarly with the use of the pure-magnesium rod in intact femora (Supplementary Fig. 1 ). X-ray analysis showed that at week 4 after implantation, both the width and area of callus in the Mg-IMN-implanted group were significantly larger than those in the IMN group, although no difference between the two groups was found at week 6, 8 or 12 (Fig. 5a,b) . Micro-CT results showed greater TV and BV, but lower BV/TV, in the Mg-IMN group, as compared to the IMN group, at week 4 ( Fig. 5c and Supplementary Fig. 7a ). At later weeks after implantation, the TV of the Mg-IMN group was lower and no longer different than that of the IMN group (Fig. 5c) . The BV of the Mg-IMN group, however, remained higher than the control group at week 8 after implantation, but by week 12, there was npg no difference in BV between the two groups (Fig. 5c) . The BMD of TV in the Mg-IMN group was lower at week 4, but higher at week 12, than that of the IMN group (Fig. 5c) . These results suggested that more callus tissue was formed at the early stage of fracture healing, and that the mineralization process was accelerated at later stages in the Mg-IMN group, as compared to the IMN group. Importantly, a four-point bending biomechanical test at week 12 showed a significantly greater maximum compressive load of the femoral shafts in the Mg-IMN group than in the IMN group (Fig. 5d) . Histomorphometric analysis suggested a typical pattern of secondary fracture healing, with callus formation, intramembranous ossification and endochondral ossification identified in all the samples (Fig. 5e,f and Supplementary Fig. 7b ). More periosteal woven bone, accompanied by elevated CGRP expression in the callus, at week 2 and more endochondral tissue at week 4 were seen in the Mg-IMN group relative to the IMN group (Fig. 5e,f and Supplementary  Fig. 7c) . From week 8 to 12, woven bone and endochondral tissue were gradually replaced by lamellar structure bridging the fracture gap (Supplementary Fig. 7b ). Polarized light images to identify collagen fibers revealed a better alignment of the collagen fibers inside the callus in the Mg-IMN group at week 4, as compared to that in the IMN group (Fig. 5f ). More bright fibers and regular lamellar bone was found in the Mg-IMN group than in the IMN group, indicating advanced remodeling with better lamellar alignment, and therefore, presenting a superior mechanical property in the Mg-IMN group. Moreover, calcein/xylenol double labeling suggested accelerated new-bone formation in the Mg-IMN group from week 4 to 8, as compared to the IMN group (Fig. 5g,h) . At week 12, the ratio of xylenol/calcein staining of the Mg-IMN group was significantly lower than that of the IMN group, suggesting the formation of mature lamellar bone tissue (Fig. 5g,h) . Consistently with results in vitro, the expression of SP7 in facture callus was substantially higher in the Mg-IMN group than in the IMN group, with no difference in RUNX2 expression between the two groups at Fig. 7d ). In addition, double staining for the proliferation marker Ki67 and the osteoblast marker RUNX2 showed a significantly (P < 0.001) larger number of cells at week 2 expressing both Ki67 and RUNX2 in the fracture callus of the Mg-IMN group than in that of the IMN group ( Supplementary  Fig. 7e ). Consistently, in cells of the osteoblast line MC3T3-E1, the addition of CGRP (10 −10 M) in culture medium promoted greater cell proliferation, as compared to control treatment ( Supplementary  Fig. 7f ). Such enhanced proliferation of osteoblasts might underlie the larger callus size observed at an early stage of fracture healing in Mg-IMN-implanted femora (Fig. 5a,b) . Given that CGRP sensory nerves are associated with pain, we tested pain levels in rats that received implantations by measuring the alternation of gait pattern, using the automated CatWalk system 36, 37 . In both IMN and Mg-IMN groups, the limb idleness index (LII) score increased and the print area (at the implanted side) decreased at week 1 after implantation, as compared to that before the surgery, indicating pain (Supplementary Fig. 8 ). However, neither LII nor print area differed between the Mg-IMN and IMN group at weeks 1 and 2 (Supplementary Fig. 8a,b) , which suggests similar gait patterns and pain levels, even though at day 4, CGRP expression was considerably higher in the Mg-IMN group than in the IMN group ( Supplementary  Fig. 8c ). Because aberrant sprouting of nerve fibers can also cause pain, we examined the growth of nerve fibers 1-14 d after surgery. The expression of growth-associated protein 43, a marker for newly generated nerves 38 
npg
(P < 0.001) lower at day 7 in the Mg-IMN group than in the IMN group (Supplementary Fig. 8d) . No difference in protein gene product 9.5, a marker for mature nerves 38 , was found between the two groups from day 4 to day 14 ( Supplementary Fig. 8d ).
CGRP receptor mediates Mg-IMN-promoted bone-fracture healing
To confirm the role of CGRP and its receptor in Mg-IMN-facilitated bone-fracture healing, we performed Ramp1 knockdown and overexpression in vivo, in conjunction with Mg-IMN implantation. Radiographs (Fig. 6a) and safranin O staining (Fig. 6b) showed that Mg-IMN-facilitated bone-fracture healing was further enhanced by AdV-Ramp1-induced overexpression and abrogated by AdV-shRamp1-induced knockdown of Ramp1, as compared to cotreatment with a control vector. In addition, aberrant fibrous tissue was found to be filling the fracture gaps in the femora with Ramp1 knockdown (Fig. 6b) .
We also performed a four-point bending biomechanical test to determine the strength of the healing fracture in these different treatment groups. We found that the maximum compressive load was significantly lower in AdV-shRamp1-treated, and higher in AdVRamp1-treated femora, with Mg-IMN implantation, as compared to those treated with AdV-NC, at week 4 after surgery (Fig. 6c) .
DISCUSSION
Studies of humans and other species have suggested the potential of magnesium-based alloys or BMG in the promotion of bone formation 3, 10, 12, [39] [40] [41] [42] , yet the underlying mechanism(s) for this beneficial effect remains unexplained. The present study has provided compelling evidence from findings both in vitro and in vivo for a contribution of magnesium to the robust promotion of bone formation and enhancement of fracture healing with the underlying mechanisms elucidated. To a great extent, the beneficial effects of magnesium are mediated by CGRP, a neuropeptide released from the sensory neuronal endings in the periosteum of the long-bone shaft. Although it has long been known that the central nervous system has an important role in the regulation of bone formation 43, 44 , the exact role of sensory nerves in this process has remained elusive. Here a previously unrecognized CGRP-mediated cross-talk pathway between peripheral nerves and PDSCs has been identified as a major mechanism underlying magnesium-induced bone formation (Fig. 6d) .
A few points from our findings support the involvement of CGRP sensory nerves in the beneficial effects of magnesium. First, magnesium-induced bone formation was largely reduced by destroying the sensory nerves or by removal of the periosteum, where a large number of sensory nerves exist. Second, magnesium induced abundant expression of neuron-derived CGRP in the newly formed bone. Studies on DRG neuronal cultures suggest that such an effect of Mg 2+ on CGRP occurs through (i) MAGT1-and TRPM7-mediated Mg 2+ -entry into neurons and (ii) Mg 2+ -facilitated CGRP-vesicle aggregation at synapses, probably by promoting actin polymerization. Importantly, pharmacological inhibition of the CGRP receptor in vivo or the silencing of its related genes (Calcrl or Ramp1) attenuated the new bone formation induced by magnesium implants (magnesium rod or Mg-IMN), whereas overexpression of Calcrl or Ramp1 in vivo enhanced the beneficial effects of magnesium implants. Of note, in addition to constituting the CGRP receptor with RAMP1, CALCRL can also be co-expressed with RAMP2 to form a receptor for amylin, which is known to inhibit bone resorption 45 . However, gene manipulation of Calcrl or Ramp1 showed similar effects on Mg-induced bone formation, which suggests the involvement of CGRP instead of amylin. Moreover, in isolated PDSCs, the key cell type involved in osteogenesis 18, 20 , CGRP promoted osteogenic differentiation through CGRP-receptor-coupled cAMP activation of CREB1 and SP7, transcription factors essential to osteogenesis 35, 46, 47 . Of note, our results both in vitro and in vivo suggest that CGRP or magnesium implant only upregulates SP7 but not RUNX2, another downstream target of CREB1 important for osteogenesis 34 , which suggests the specific activation of CREB1 and SP7, leading to osteogenic differentiation (Fig. 6d) . Further study is required to understand why RUNX2 is not responsive to magnesium or CGRP and whether other reported CREB1-regulated pathways (for example, BMP2, Wnt/β-catenin) are involved 48, 49 . Taken together, these results are consistent with previous findings showing that CGRP insufficiency, accompanied by magnesium loss in the bone, is associated with delayed fracture healing in aged animals 50, 51 . Sensory nerves secrete CGRP and promote callus formation and bone remodeling, whereas a lack of CGRP + nerve fibers leads to delayed union or nonunion 21, 52, 53 . Therefore, the presently identified role of magnesium in promoting CGRP-mediated osteogenesis has suggested its therapeutic implication in the repair of osteoporotic bone fracture or other bone diseases. Nevertheless, whether a magnesium implant or CGRP influences other cell types, such as chondrocytes, to contribute to osteogenesis awaits further investigation. It would also be important to test whether systemic administration of magnesium (such as oral pills) would promote CGRP mobilization and thus be a potential nutraceutical method for bone disorders.
A progression of the present study would be the development of a Mg-IMN system to provide both mechanical support and osteogenic benefits for repairing long-bone fracture. It is known that closed-bone fracture is commonly seen in patients with osteoporosis, the so-called low-energy osteoporotic fractures. As a proof-of-concept experiment, we used a closed-fracture model where the injury is limited to the fractured bone, with no injury to the periosteum. In addition, Mg-IMN was implanted with the drilled holes adjacent to the fracture line, ensuring that the released Mg 2+ is delivered mostly to the wound. As expected, higher magnesium content was detected in peripheral fracture callus in the Mg-IMN group than in the IMN group. The way in which the released Mg 2+ is transported to the periosteal region can be explained by the diameter of Mg 2+ (<300 pm) being much smaller than that of Harversian's or Volkmann's canals within the cortical bone (in microscale level), as reported in our earlier study 54 . In addition, Mg 2+ might diffuse through the fracture gaps (Fig. 6d) .
The outcome seen here with Mg-IMN treatment is promising. First, Mg-IMN accelerated bone remodeling, as indicated by significant increases in callus, BV and the ratio of xylenol/calcein osteoid staining at an early stage (week 4). Second, mechanical strength is improved by Mg-IMN. At week 12, although the xylenol/calcein staining ratio is lower in the Mg-IMN group than in the IMN group, probably owing to the completion of bone remodeling, a higher BMD and better lamellar bone morphology were achieved with Mg-IMN treatment, indicating greater mechanical strength than that achieved with IMN treatment. This result is also consistent with a previous report showing better alignment of matrix collagen in Mg 2+ -treated cells 55 . Of note, in the present study, new bone is formed mainly in the periosteal region, which, even with a small-scale increase in BV, might translate into substantial improvement in biomechanical properties (that is, bending or torsional strength), as previously reported 56, 57 . Indeed, biomechanical testing confirmed a much stronger mechanical property of the bone in the Mg-IMN group at the end of experimental time frame (that is, at week 12 after implantation). In addition, the pain levels in rats with Mg-IMN treatment showed no difference relative to controls, which suggests the suitability of Mg-IMN for clinical uses.
In conclusion, the present study has revealed a CGRP-involved mechanism that underlies the osteogenic effects of magnesium-based implant. An innovative Mg-IMN system has been developed and has shown therapeutic potential for bone injuries, in particular, for the commonly seen low-energy osteoporotic fracture. With the development of specific cell or tissue targeting systems 58 , it might also be possible to deliver Mg 2+ or recombinant CGRP to specific healing sites in the bone. Therefore, the present findings could have broader implications in the treatment or prevention of other bone diseases or injuries, such as highenergy fractures resulting from sports injuries and other traumas.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
General experimental approaches. All animal experimental protocols used in the present study were approved by the Animal Experimentation Ethics Committee of the Chinese University of Hong Kong. Sex-and age-matched animals were divided into groups randomly. No samples, rats or data points were excluded. Analyses were performed in a nonblinded fashion.
Fabrication of magnesium rod. Ultrapure (99.99%) magnesium cylindrical rods (1.28 mm in diameter, 20 mm in length) were provided by the Department of Materials Science and Engineering in Peking University (China). The magnesium rods were prepared by copper-mold injection casting under argon atmosphere using published protocol 11 . In brief, magnesium was placed in a quartz tube and melted. Then the melted magnesium was injected quickly into a copper mold, and finally, rod samples were obtained. Differential scanning calorimetry (Q100, Thermal Analysis, USA) was used to identify the thermal dynamic properties of the samples. Magnesium rods were sterilized by immersing into 70% ethanol for 30 min before implantation.
Intramedullary implantation in rat femur. Three-month-old female Sprague Dawley (SD) rats were used for surgical intramedullary implantation, as previously reported 3, 12 . After the rats were anesthetized by intraperitoneal injection with ketamine (75 mg/kg) and xylazine (10 mg/kg), the right knee of the rat was exposed and a tunnel with a 1.2-mm diameter and 30 mm in length was drilled from the patellofemoral groove of the distal femur along the axis of the femoral shaft. A sterilized magnesium or stainless steel rod was inserted into the femur canal. The wound was sutured, and the rats were housed in an environmentally controlled animal-care laboratory after surgery. Serial radiographs were used to scan the operated distal femora weekly, up to week 16 after operation, for both general inspection and analysis. In some animals, BIBN4096BS (300 µg/kg body weight, Shanghai Haoyuan Chemexpress, Shanghai, China) conjugated with indodicarbocyanine (Cy5) was injected into the middle site of the right femoral shaft immediately after implantation and every other day for 2 weeks. mX-ray fluorescence (mXRF) measurements. µXRF measurements were performed using the scanning X-ray microscope installed at beamline ID21 of the ESRF (Grenoble, France) 59 . The primary X-ray beam energy was set to 2.1 keV and focused down to a microprobe (0.5 × 0.8 µm 2 ). The flux was 2.6 × 10 9 photons/s. A first mirror made of Ni was used, which passes the primary energy (E1) and the third harmonic (E3) of E1 (E3/E1 intensity ratio, ~1/10). XRF and scattered radiation were collected with an energy-dispersive silicon drift detector with an active area of 80 mm 2 (XFlash 5100, Bruker, Germany), subsequently normalized by the intensity of E1. Acquisition time per point was 100 ms. The step width for collecting the XRF maps (25 adjacent lines with 5 µm spacing) was set to 5 µm. The use of the dual-energy X-ray beam configuration allowed for high excitation of magnesium and calcium with the 2.1 keV and 6.3 keV energy part of the X-ray beam, respectively. To directly compare different measurements, magnesium-to-calcium ratio was calculated from the line scans performed from the bone-marrow cavity (inside) to the periosteum (outside).
Scanning electron microscopy-energy-dispersive spectroscopy. Specimens embedded in methylmethacrylate (MMA) were sliced and polished to 100 µm in thickness for sputter coating. The elemental composition at the selected regions of interests was determined by scanning electron microscopy-energy-dispersive spectra (HITACHI SU8010; Japan).
immunofluorescence staining was used for determining the expression of CGRP. Rabbit polyclonal antibody to CGRP was purchased from Abcam (ab47027, working with a dilution of 1:200).
The sequential fluorescence labeling was used to evaluate new-bone formation rate or bone remodeling during fracture healing, as we previously reported 58, 61 . Calcein green (5 mg/kg, Sigma-Aldrich, USA) was subcutaneously injected into rat femora 7 d before xylenol orange (90 mg/kg, Sigma-Aldrich, USA) was injected in the same way. Another 7 d afterwards, rats were sacrificed, and femora were collected and embedded in MMA without decalcification and sectioned into thick sections (200 µm). The tissue sections were further ground and polished to 100 µm for the evaluation of new-bone formation rate under a fluorescence microscope (Leica Q500MC, Leica, Germany). To calculate the temporal change of new bone formation, 5 mm proximal and 5 mm distal to the fracture line was chosen as the ROI for quantification of new bone formation. The ratio of area labeled with xylenol orange to area labeled with calcein green was determined using ImageJ.
Fracture callus was digitalized under light microscope (Zeiss, Germany) and then quantified by ImageJ for bone-tissue-area fraction and cartilage-tissue-area fraction. A polarized light microscope was also applied to analyze the collagen birefringence arrangement in decalcified sections.
Detection of neuropeptides by ELISA. The femora of the rats with and without magnesium implantation were harvested, and the mid-shaft of 1 cm in length was prepared for ceramic morta, ground into mud before putting into 15-ml plastic tubes. Pre-cool lysis buffer (1 ml, with 1M hydrochloric acid) was added into the tube and put into the ice bath. After oscillation and homogenization for 1 h, the buffer was transferred into a 1.5-ml tube and centrifuged at 12,000 rpm for 30 min. The supernatant was collected for BCA protein quantitative analysis, and 200 µl of supernatant from each specimen was used for the quantitative detection of CGRP (Elabscience Biotechnology, USA), substance P, neurokinin K and galanin (LifeSpan Bioscience, USA) by ELISA kit. The ELISA result was normalized by the concentration of total protein for each specimen.
Detection of CGRP expression in dorsal root ganglions. The right DRGs at lumbar L4 of SD rats were isolated according to a published procedure 62 . Briefly, after the administration of an overdose of phenobarbital, laminectomy was performed to remove the vertebral canal roof and to expose DRGs and the spinal cord. The isolated L4 DRG was transferred into a tube with 10 ml of PBS (containing 10% penicillin-streptomycin-neomycin (PSN), from Life Technologies) without Ca 2+ /Mg 2+ . After fixation in 4% formalin solution for 24 h, the DRGs were dehydrated in 30%-sucrose solution. Cryosections (10-µm thick) were prepared for immunofluorescence staining of CGRP (Abcam, ab47027, 1:200).
Primary culture of DRG neurons. We isolated sensory neurons from L3-L5 DRGs by sequential digestion using papain, type I collagenase (1 mg/ml) and 0.25% trypsin solutions by following reported protocols [62] [63] [64] . Morphologically distinct phase-bright neurons (50%) and phase-dark glial cells (50%) were observed right after isolation. These isolated cells were re-suspended in F12 medium and plated on round-glass slices (2.5 cm in diameter) coated with laminin (20 ng/ml, Life Technologies) and poly-d-lysine hydrobromide (50 ng/ml, Life Technologies) at a density of 5,000 cells/ml. 4 h after plating, the culture medium was replaced with F12 medium containing 10% FBS, 1% PSN, 20 ng/ml NGF (Sigma-Aldrich, USA), 10 −5 M fluorodeoxyuridine (Sigma-Aldrich, USA) and 10 −5 M uridine (Sigma-Aldrich, USA) for another 72 h in incubation, before the large phase-bright DRG neurons were used for further tests.
Detection of synaptic vesicles in DRG neurons. We used fluorescent dye FM1-43 (N-(3-triethylammoniumpropyl)-4-(4-(dibutylamino)styryl) pyridinium dibromide) (Biotium, Hayward, USA) to label and trace the change and movement of synaptic vesicles in live DRG neurons, as previously reported 65 . The isolated DRG neurons were seeded on cover glasses. On the experimental day, the cells were washed twice with a high K + and Mg 2+ -free (HKMF) Margo's solution containing (in mM): 45 NaCl, 90 KCl, 2.5 CaCl 2 , 20 HEPES acid and 10 glucose, before incubation with FM1-43 (10 µM) in HKMF Margo's at 37 °C for 15 min. Afterwards, cells were washed with Mg 2+ -free Margo's solution containing (in mM): 130 NaCl, 5 KCl, 2.5 CaCl 2 , 20 HEPES acid and 10 glucose, for three times before being transferred to a mini-chamber and mounted to a confocal microscope (Zeiss, Germany). MgCl 2 (1-2 mM) or NMDG-Cl (2-4 mM) as a control was added to the Mg 2+ -free Margo's bath in the presence or absence of cytochalasin B (20 µM). Z-stack (0.8-1 µm intervals) confocal images of the DRG neurons were captured every 2-10 min. The Z-stack series was projected into a single image for each time-point capture by the software Exciter (Carl Zesis, Germany), the fluorescence intensity of which was analyzed and quantified by the software ImageJ (version 1.42q, NIH, USA).
Measurement of intracellular Mg 2+ in DRG neurons. DRG neurons were seeded on cover glasses 72 h before the experiments. The cells were incubated in the Mg 2+ -free Margo's solution supplemented with 2 µM Mg-Fura2 (Life Technologies, USA) and 1 µM Pluronic F-127 (Life Technologies, USA) for 30 min before being washed with the Mg 2+ -free Margo's solution and stabilized for another 30 min at room temperature. After the cells were transferred to a mini-chamber that was mounted to a microscope (Nikon Eclipse Ti, Japan) equipped with a CCD camera (Spot Xplorer, USA) and a Fluor 20X objective lens (0.75 NA, Nikon, Japan), Mg-Fura2 was excited at 340 nm and 380 nm, respectively. Fluorescence signals were monitored, and pictures were taken every 5 s by a microscope (Nikon Eclipse Ti, Japan). The fluorescence ratio was measured by the software MetaFluor (USA).
ATP assay. ATP concentrations were determined using a luminescence ATP-detection assay system (ATPLite, PerkinElmer, USA), according to the manufacturer's guidelines.
2,5-fluorescein isothiocyanate (FITC) staining for confocal imaging. FITCstained samples were prepared according to our established protocol 66 . In brief, rat femora were fixed and dehydrated and then 1% FITC (Sigma-Aldrich, USA, cat. #F7250) in 100% ethanol was used to immerse the samples overnight. The samples were further dehydrated with 100% ethanol and acetone, followed by plastic embedding and sectioning. The SP5 Leica confocal microscope was used to gather stackable images.
Isolation and culture of rat PDSCs. Femora of 1-month-old female rats were collected, and periosteum from mid-shaft to distal femur was collected and put into Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS and type I collagenase (1 mg/ml). The periosteum was digested in a 37 °C incubator for another 8 h, and the filtered medium was centrifuged (1,000g for 5 min) to collect the periosteal cells. The mixed cells were plated at an optimal low-cell density (1,000 cells/cm 2 ) in a humidified atmosphere at 37 °C, 5% CO 2 to form colonies. At day 2 after initial plating, the cells were washed twice with PBS to remove nonadherent cells. At days 7-10, large round colonies (>200 cells) were trypsinized and mixed together as passage 1. The collected cells were subcultured after reaching 80-90% confluence. Cells at passage 3-5 were used for further experiments.
Fluorescence staining for stem cell markers. PDSCs were seeded on glass slides at a density of 10,000 cells/slide and cultured for 24 h. After the cells were fixed and blocked with 5% BSA solution for 1 h, the monoclonal rabbit anti-rat primary antibody to CD44 (Abcam, ab24504), CD90 (Abcam, ab92574) and CD105 (Abcam, ab107095) were incubated with cells with a dilution of 1:500 (v/v) at 4 °C overnight. After washing with PBS twice, Cy5-conjugated goat anti-rabbit secondary antibody with a dilution of 1:1,000 was applied to the slides for 1 h. The cells were washed in PBS, counterstained with DAPI and examined by a fluorescence microscope (Leica Q500MC, Leica, Germany).
Cell proliferation assay. PDSCs or MC3T3-E1 clone 4 cell line (ATCC CRL-2593, negative for mycoplasma contamination) were plated at a density of 4,000 cells/cm 2 in a 96-well plate and incubated in a 37 °C incubator with supplementation of 5% CO 2 . Cell proliferation was assessed using MTT assay (SigmaAldrich, USA) at days 1, 2 and 3. The absorbance at 570 nm was measured and reported 67 . 10 −16 to 10 −8 M CGRP (Abcam, USA, cat. #ab47101) was used.
Real-time PCR. PDSCs were plated at a density of 4,000 cells/cm 2 in a 12-well plate and cultured in basal culture medium until 90% confluence. High-glucose npg DMEM supplemented with 10% FBS, 1 nM dexamethasone, 50 µM ascorbic acid, and 20 mM β-glycerolphosphate (the last three chemicals were from Sigma-Aldrich, USA) was used as osteogenic induction medium. At day 14 after osteogenic induction, PDSCs were harvested and homogenized for RNA extraction using the RNeasy mini kit (Qiagen, Germany) 58 . Total mRNA was reverse-transcribed to cDNA using the First Strand cDNA kit (Takara, DaLian, China). Then, 1 µl of total cDNA of each sample was amplified in a 10-µl reaction system (for 384-well plate) containing the SYBR Green qPCR SuperMix-UDG and specific primers (Supplementary Table 2) for Opn, Bglap, Alp and Actb using the ABI 7900HT real-time PCR system (Applied Biosystems, USA). The expression of the target gene was normalized to that of Actb. Relative gene expression was calculated using the 2 −∆CT formula.
Alizarin red and ALP staining assay. PDSCs were plated at 4,000 cells/cm 2 in a 12-well plate and cultured in complete medium until confluence. At day 14 after osteogenic induction, the cells were fixed for AR and ALP staining (SigmaAldrich, USA) and subsequent imaging evaluation using HP Scanjet G3110 Photo Scanner, as described previously 67 .
Western blotting. Specific primary antibodies against CALCRL (Abcam, ab83697), RAMP1 (Abcam, ab203282), RUNX2 (Abcam, ab76956), SP7 (Abcam, ab94744), pCREB1 (Abcam, ab32096) and β-actin (Abcam, ab8227) were diluted to 1:1,000 (v/v) in blocking buffer for incubation of the membranes overnight, respectively. After incubating with HRP-labeled secondary antibodies against the species of primary antibodies under a dilution of 1:8,000 (v/v) for 1 h at room temperature, HRP signals were detected using an enhanced chemiluminescence kit (Amersham Biosciences, USA).
Conditioned medium from the DRG neurons. Isolated DRG neurons were seeded onto 6-well plates at a density of 10,000 cells/cm 2 . Once fully attached, DRG neurons were cultured in growth medium (containing 1 mM of Mg 2+ ) supplemented with additional MgCl 2 (1 mM) or NaCl (2 mM) as a control for 72 h, after which 2 ml of medium from each well was collected and concentrated by a column (Millipore) into a final volume of 100 µl. The concentrates were diluted at 1:100 with osteogenic induction medium and used for osteogenic differentiation of PDSCs.
Design of the magnesium-containing intramedullary nail (Mg-IMN).
Hollow spinal needles (18 G, with an outer diameter of 1.27 mm and an inner diameter of 0.9 mm) were purchased from Terumo (Terumo, USA). Holes were drilled by electric sparks burning in vertical directions at the transverse section with an equal distance of 0.5 mm by Ziyoujian (Shenzhen, China). Afterward, an ultrapure magnesium rod was inserted into the needles. In the finite elemental analysis (FEA) analysis, 10-node tetrahedron element, SOLID 92, was chosen to mesh the needle in ANSYS (ANSYS, Canonsburgh, PA, USA). The size of the mesh element was 0.05 mm. The mechanical properties of the needle (modulus as 210 GPa, poison ratio as 0.3) were input into the software. A parallel vertical force of 20 N at each loading point was applied downwardly to the needle.
Establishment of closed-fracture model in osteoporotic rats. 6-month-old female rats were used to establish standard ovariectomy-induced osteoporosis model, according to our well-established protocols 1,68 . Closed femoral fracture was established on the right femur of rat, according to our published protocol 1 . The rats were randomly divided into Mg-IMN and IMN groups. Mg-IMN or IMN was inserted into the fractured femur along its vertical axis from the patellofemoral groove to the greater trochanter. Analgesia was given every day for 3 d after surgery for pain relief.
Measurement of nerve sprouting. Primary antibodies for GAP-43 (Abcam, ab16053, 1:1,000) and PGP-9.5 (Abcam, ab8189, 1:1,000) were purchased from Abcam. At day 4, day 7 and day 14 after fixation, bone specimens 5 mm above and below the fracture line were collected for protein extraction and measurement of GAP-43 and PGP9.5 expression by western blotting, as described above.
Radiographic analysis of fracture callus. The radiographs were analyzed according to our established protocol 61 . Radiographic healing was defined as complete bridging of the mineralized callus. Callus width (CW) was defined as the maximum width of callus, and callus area (CA) was equal to the size of radiopaque area of callus as shown in the radiographs. Both CW and CA were measured on a lateral radiograph of each rat by using ImageJ. The measurement for each callus was repeated three times, and the average was used for statistical analysis.
Biomechanical test. Four-point bending test was performed for evaluating the fracture-healing quality using a mechanical testing machine (H25KS Hounsfield Test Equipment, Redhill, Surrey, UK), as described in our previous study 61 . In brief, the femora were placed with the anterior-posterior direction on the lower supporting bars at 26 mm apart, and the upper bars at 10 mm apart, flanking the fracture callus. A compression load was applied at a compression speed of 5 mm/min until failure. The maximum compressive load was derived from the load-deformation curve in built-in QMAT software (Redhill, Surrey, UK).
Gait analysis for pain measurement. Automated gait analysis was performed before surgery as a baseline, 1 week and 2 weeks after surgery, using a CatWalk system (Noldus, Wageningen, Netherlands), as previously described 36, 37 . Briefly, we trained the rats to cross the CatWalk walkway daily for 2 d before the implantation of magnesium or stainless steel. After setting the thresholds to pick up the illuminated contact prints, each rat was placed individually in the CatWalk walkway. The rats were allowed to walk freely. Video recording of paw prints was automatically triggered when the rats entered the ROI. Recorded runs with a steady walking speed (variation, < 30%) were accepted as compliant runs for paw-print auto-classification as left forelimb (LF), right forelimb (RF), left hind limb (LH) and right hind limb (RH) by the built-in software. After checking the correctness of classification manually, we only further analyzed the runs with normal alternate footfall pattern (LF→RH→RF→LH). Limb idleness index, another parameter for the assessment of pain 36 , was calculated from the raw data. Animals for pain test were not given analgesia.
Statistical analysis. Sample size was based on preliminary data as well as on observed effect sizes. Data are presented as means ± s.e.m., with n as the number of tissue preparations, cells or animals. Unpaired or paired two-tailed Student's t test was used for comparison between two groups. Data distribution was previously tested with the Shapiro-Wilk test. One-way or two-way ANOVA with relevant post hoc tests was used for multiple-group comparisons. Box-and-whisker plots were used to describe the entire population without assumptions about the statistical distribution. P < 0.05 was considered to be statistically significant. GraphPad Prism software (Version 6.01) was used for above statistical analysis.
